mybio
An ongoing news involves Rusan Pharma investing 300 Crores in MP’s new API Facility in Pithampur. This news is spreading online and everyone is trying to gather every detail about the news. A pharmaceutical company, Rusan Pharma has released a new active pharmaceutical ingredient manufacturing facility. This launch took place on Saturday in Pithampur, Madhya Pradesh. This news is spreading online and attracting everyone’s attention. What happened? What is the whole point behind the launch? We will discuss everything in this article. Let’s continue the article.
Rusan Pharma announces ₹300 crore API manufacturing plant
According to reports, the facility is poised to produce 400 API figures annually and is expected to create more than 300 jobs. The organization has invested Rs 300 million in the facility located in Pithampur Special Economic Zone. The new provision will contest Rusan Pharma’s existing API capabilities, boosting the supply of critical APIs to face the growing demand for pain and addiction management products in India. and worldwide. We will tell you more important details about the news, which you will find in the next part of the article.
On the basis of the report, the Organization is known for its increasingly innovative products, such as Buprenorphine Sublingual Tablets and Buprenorphine Naloxone Sublingual, used in the treatment of drug abuse, Lidocaine Transdermal , Apomorphine injection and used to treat Parkinson’s disease, Buprenorphine and native formulations of Fentanyl. Not only that, Nicotine transdermal patches are also created by them to quit smoking. Kunal Saxena, who is serving as managing director of Rusan Pharma, commented that with an investment of around Rs 300 crore in two phases, this new API facility will scale up the existing API manufacturing capacity at theirs from 40 tons. in Ankleshwar to 400 tons in Pithampur. Scroll down the page to find out more information about the news.
Furthermore, the company’s statement puts forward that its current GMP license for the supply of its API-terminated formulation is capable of meeting 90% of global demand. The company is approved by a number of authorities, such as the South African Health Products Regulatory Authority, Health Canada, the European Union, the United Arab Emirates and the United Arab Emirates. Australian Therapeutic Goods Administration. If we have further details, we will notify you in advance at the same location. Please follow us for more updates.
Categories: Trending
Source: Tekmonk Bio, Make Money Blogging
GIPHY App Key not set. Please check settings